Biomolecular Analysis for Predicting Response to Regorafenib

Tumor Biomolecular Analysis for Defining Predictive Factors for Response to Regorafenib in Recurrent Glioblastoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05759195

Acronym

RegoRec

Enrollment

Registered

2023-03-08

Start date

2021-01-07

Completion date

2024-12-31

Last updated

2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma, Glioblastoma, IDH-wildtype

Keywords

regorafenib, NGS, predictive biomarker

Brief summary

The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.

Interventions

DIAGNOSTIC_TESTBiomolecular tumor analysis

NGS analysis, other molecular analyses on FFPE tumor tissue

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. recurrent glioblastoma after surgery and chemoradiation with temozolomide; 2. indication to treatment with regorafenib per standard of care; 3. written informed consent.

Exclusion criteria

None.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	through study completion, an average of 3 years	Interval between tumor diagnosis and death or end of follow-up

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026